Synchronous cholangiocarcinoma and cervical squamous cell carcinoma managed via a multidisciplinary approach: A case report

Table 1 Concise timeline of key diagnostic and therapeutic events

Date (2024-2025)	Event
March 13, 2024	First presentation with post-menopausal bleeding
March 14, 2024 to March 25, 2024	Crosssectional imaging (contrast CT/MRI) and PET/CT reveal solitary segment-V liver lesion; tissue confirmation: Cervical punch biopsy - squamouscell carcinoma; Ultrasound-guided liver biopsy - intrahepatic cholangiocarcinoma; multidisciplinary tumor board agrees treatment sequence
March 29, 2024	Laparoscopic partial hepatectomy (segment V and right posterior lobe) and regional lymph-node dissection; R0 resection achieved
April 4, 2024	Post-operative abdominal infection (Streptococcus viridans) managed with drainage plus IV vancomycin + cefoperazone/sulbactam
May 2, 2024 to June 24, 2024	Pelvic radiotherapy for FIGO IB1 cervical SCC: External-beam IMRT 45 grays/25 fractions (May 2, 2024 to June 6, 2024); HDR 192Ir intracavitary brachytherapy 35 grays/7 fractions to point A (June 10, 2024 to June 24, 2024)
August 6, 2024	Commenced systemic therapy: Lenvatinib 8 mg quaque die + capecitabine 1.5 g bis in die (day 1-14, quaque 21 die) + camrelizumab 200 mg IV quaque 3 weeks
January 1, 2025	8th (final) camrelizumab cycle administered; capecitabine and lenvatinib dispensed for last course
March 22, 2025	12-month follow-up: Contrast-enhanced CT negative for recurrence/metastasis; tumor markers normal; Karnofsky 80

CT: Computed tomography; MRI: Magnetic resonance imaging; PET: Positron emission tomography; FIGO: International Federation of Gynecology and Obstetrics; SCC: Squamous cell carcinoma; IMRT: Intensity-modulated radiation therapy; HDR: High dose rate.